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Abstract
Myotonic dystrophy type 1 (Steinert's disease) is a multisystem disorder with autosomal dominant
inheritance. This disease is associated with the presence of an abnormal expansion of a cytosine
thymine-guanine (CTG) trinucleotide repeat on chromosome 19q13.3. Because of rhythmic
complications, the place for systematic electrophysiological study (EPS) has to be discussed.
Manuscript
Myotonic dystrophy type 1 (DM1 = Steinert's disease) is a
multisystem disorder with autosomal dominant inherit-
ance. This disease is caused by an unstable expansion
mutation of the cytosine thymine-guanine (CTG) trinu-
cleotide repeat situated in the 3' non-coding exon of a
gene that encodes a serine-threonine protein kinase
(DMPK). The incidence of DM1 is estimated to be 1/8000
births [1]. Patients disclose features muscular disorder
including myotonia, progressive muscular weakness and
wasting associated to a multi-systemic disorder (cataract,
hypogonadism, gastrointestinal disorders, and diabetes).
Patients with DM1 have a high incidence of sudden car-
diac death (SCD) because of ventricular arrhythmias and/
or complete heart block [2,3]. Histopathology studies dis-
close fibrosis in the conducting system and in the sino-
atrial node associated with myocyte hypertrophy and fatty
acid infiltration.
Groh WJ et al. reported in a mean follow-up period of 5.7
years, 27 sudden deaths in a study including 406 adults'
patients with DM1. There is a consensus to explore symp-
tomatic patients with DM1. Electrophysiological study
(EPS) is an invasive procedure for assessing conduction
abnormalities and risk of SCD (with ventricular stimula-
tion). This procedure should be considered in case of syn-
cope, family history of sudden death, sinus node
dysfunction (sinus pause > 3 seconds), ventricular
arrhythmias and electrocardiogram (ECG) abnormalities
suggesting intra or infrahissian conduction disturbances
[4,5]: left bundle branch block, bifascicular or trifascicular
block, second or third degree atrio-ventricular (AV) block.
Pacemaker implantation should be considered in sympto-
matic patients with conduction abnormalities. Implanta-
ble cardioverter defibrillator (ICD) has proved its efficacy
to prevent SCD due to ventricular arrhythmias. An ICD
implantation should be considered if spontaneous sus-
tained VT was noted.
In asymptomatic patients, prediction of cardiac events is
not easy. About asymptomatic patients, systematic EPS is
performed to measure the HV interval and to implant a
pacemaker before the occurrence of a high degree AV
block if a first degree infra-hissian AV block has been
found even if the use of the HV interval to determine the
need for pacing is still controversial. Lazarus et al. pro-
posed a prophylactic implantation of a pacemaker when
the HV interval is ≥70 ms [4].
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Non invasive tests may be used in asymptomatic patients
for evaluating the risk of rhythmic complications. ECG
may be useful in predicting SCD. In the study reported by
Groh WJ et al. [6], MD1 patients with severe abnormality
(ECG with at least one of the following features: rhythm
other than sinus, PR interval of 240 msec or more, QRS
duration of 120 msec or more, or second-degree or third-
degree AV block) were at risk for sudden death [6]. Non-
invasive ambulatory ECG is another procedure for assess-
ing asymptomatic patients. According to Sá MI. et al.,
non-invasive ambulatory ECG in patients with myotonic
dystrophy type 1 should be performed on a regular basis,
at intervals not greater than six months [7]. In a study
including 36 patients with myotonic dystrophy type 1, Sá
MI et al. found a high prevalence and changes between
baseline and follow-up Holter ECG that justified perma-
nent pacemaker implantation in 11 patients [7]. Heart
rate turbulence may be considered as a non-invasive risk
predictor of ventricular tachy-arrhythmias in Steinert's
disease [8]. Hardin et al. [9] investigated the relationship
between autonomic nervous system function, using holter
monitoring with heart rate variability (HRV) analysis, and
the clinical and genetic factors in patients with myotonic
dystrophy type 1. The authors found a decline in HRV
with increasing age and the precise genetic abnormality.
Signal averaged ECG is another non-invasive procedure
for analysing risk stratification in asymptomatic patients.
The prolongation of total QRS duration on signal aver-
aged ECG in myotonic dystrophy is primarily related to
delayed activation of the His and Purkinje tissue and not
to the development of true late potentials. Some non-
invasive test can predict the occurrence of AV block with
the same efficacy than HV measurement to suppress sys-
tematic electrophysiological study. According to Babuty D
et al. [10], association of QRS duration ≥100 ms with low
amplitudes signals (< 40 μV)  ≥ 36 ms may identify
patients with an abnormal HV interval with good sensitiv-
ity (80%) and specificity (83. 3%). Genetic analysis is also
a non-invasive assessment of cardiac risk. The severity of
cardiac myopathy in DM 1 seems to be correlated with age
and CTG repeat length [11]. In the study reported by
Babuty D. et al., the size of the DNA mutation was longer
in the abnormal HV interval group than in the normal HV
interval group (3.5(1.8) vs 2.2 (1.0) kb, p < 0.02) [10]. For
analysing the risk of SCD in asymptomatic patients, there
is not a consensus for performing systematic ventricular
stimulation. Moreover, even in symptomatic patients it
can be difficult to base the decision of ICD implantation
on a positive EPS, given the possibility of a false positive
result. HV prolongation could be also an indirect marker
of risk of ventricular tachycardia.
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